The GPATCH11 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatic adenocarcinoma line. This loss-of-function model targets GPATCH11, a putative RNA-binding protein with a G-patch domain implicated in RNA processing. The heterogeneous polyclonal format enables functional investigation of GPATCH11??s involvement in RNA splicing and mRNA metabolism pathways in hepatocellular carcinoma without the constraints of single-cell clonal selection.
The SK-HEP-1 host cell line, originally from a hepatocellular carcinoma patient ascites, uniquely co-expresses endothelial and mesenchymal markers. This hybrid phenotype makes it a powerful model for studying liver cancer biology, including epithelial-to-mesenchymal transition, tumor heterogeneity, angiogenesis, and metastatic progression. SK-HEP-1 cells are well-suited for genetic perturbation and phenotypic assays addressing hepatocellular carcinoma mechanisms.
GPATCH11 is characterized by a G-patch domain, suggesting involvement in RNA binding and processing within spliceosome-associated complexes. Although its precise molecular partners remain unknown, GPATCH11 likely participates in RNA splicing and mRNA metabolism. In hepatocellular carcinoma, post-transcriptional regulation by GPATCH11 could influence transcripts governing tumor growth and metastasis. These knockout cells provide a necessary tool to clarify GPATCH11??s mechanistic contributions and identify its interacting factors and downstream targets.
Pairing GPATCH11 disruption with the SK-HEP-1 background creates a focused system for evaluating its role in liver cancer phenotypes that depend on endothelial-mesenchymal plasticity. The preserved polyclonal diversity mimics tumor heterogeneity, enabling robust phenotypic screening of processes like cell migration, invasion, and mesenchymal marker expression. Researchers can thus assess how GPATCH11 loss affects the metastatic potential and tumorigenicity conferred by SK-HEP-1??s unique hybrid characteristics.
These polyclonal knockout cells are ideal for RT-qPCR and western blot validation of GPATCH11 disruption and for RNA sequencing to profile transcriptomic changes in splicing and gene expression. Complementary functional assays??proliferation, migration, and invasion??directly measure hepatocellular carcinoma aggressiveness. The model also supports drug sensitivity testing and complementation studies through GPATCH11 re-expression. For technical inquiries and experimental design support, please contact Ascent Research.
